



SK Life Science Labs to Share Insights on Multiple Pipeline Programs Including SMARCA2 and p300 Selective Degraders at the BIO International Convention in San Diego

KING OF PRUSSIA, Pa. – June 4, 2024 – SK Life Science Labs, a subsidiary of SK Biopharmaceuticals, Co., Ltd., a global biotech focused on the research, development, and commercialization of treatments for disorders of the central nervous system (CNS) and cancer, will share insights on SMARCA2 Heterobifunctional Degraders and p300 Selective Degraders highlighting their potential in cancer treatment at the 2024 BIO International Convention this week in San Diego.

SK Life Science Labs presentation details at BIO 2024 International Convention are as follows:

- **Date:** Wednesday, June 5, 2024
- **Time:** 11:00am PT
- **Location:** In-booth presentation (booth #5815), Hall H, San Diego Convention Center
- **Presenters:** Zhihua Sui, Chief Scientific Officer, and Helai Mohammad, Vice President, Head of Biology

“Our preclinical stage p300 selective degraders showcase a first-in-class opportunity for therapeutic intervention by targeting CBP loss-of-function (LOF) cancers,” said Zhihua Sui, Ph.D. Chief Scientific Officer, SK Life Science Labs explaining that p300 degraders can also suppress AR signaling through an androgen-independent mechanism for treatment of prostate cancers. “Together, our data demonstrate that p300 is essential for the survival of a number of cancer cell lineages that harbor CBP LOF mutations (bladder, colon and others) and plays an important role in AR signaling pathway.”

“Our SMARCA2 selective lead degraders demonstrate remarkable oral bioavailability, potent selective degradation of SMARCA2 *in vivo*, and selective growth inhibition of SMARCA4 mutated cancer cells,” said Dr. Sui. “SMARCA4 is mutated in many cancers including non-small cell lung carcinoma, colon adenocarcinoma, bladder, and endometrial cancer.”

SK Life Science Labs is a drug discovery company with a precision medicine approach for oncology and immunology. The company's goal is to impact human health by breaking through the limits of targeted protein degradation (TPD) and expanding access to disease targets. For more information about SK Life Science Labs and to review these and other scientific presentations, please visit our website at www.skllabs.com/news-media.

###

About SK Life Science Labs

SK Life Science Labs (formerly Proteovant Therapeutics) exploits the ubiquitin-protease system (UPS) to discover and develop transformative medicines for the treatment of patients with life-altering diseases.

Protein degradation harnesses the human body's innate cellular machinery by way of the UPS to identify and mark disease-causing proteins for destruction. This promising approach provides the opportunity to target proteins of interest, many of which were previously considered undruggable. SK Life Science Labs integrates its AI-enabled target ID platform, degrader drug-hunting expertise, and MOPED™ molecular glue screening platform to advance novel protein degraders. As of August 11, 2023, SK Life Science Labs is part of SK Biopharmaceuticals. For more information, please visit www.skllabs.com.

About SK Biopharmaceuticals Co., Ltd.

SK Biopharmaceuticals is a global biotech company focused on the research, development, and commercialization of treatments to help people living with central nervous system (CNS) disorders and change the future of cancer care. Together with its U.S. subsidiary, [SK Life Science, Inc.](http://www.skllabs.com), SK Biopharmaceuticals has a pipeline of eight compounds in development. Both companies are part of SK Group, one of the largest conglomerates in Korea and one of TIME's 100 Most Influential Companies of 2023. For more information, please visit www.skbp.com/eng.

SK Biopharmaceuticals' parent company SK Inc. continues to enhance its portfolio value by executing long-term investments with a number of competitive subsidiaries in various business areas, including pharmaceuticals and life science, energy and chemicals, information and telecommunication, and semiconductors. In addition, SK Inc. is focused on reinforcing its growth foundations through profitable and practical management based on financial stability, while raising its enterprise value by investing in new future growth businesses. For more information, please visit www.sk-inc.com/en.

SK Life Science Labs

Dina Albanese

Media@SKLLabs.com

SK Life Science Strategic Alliance and Partnership Opportunities

Kiel Kim

Partnerships@SKLLabs.com